QIAGEN (NYSE: QGEN) and GENCURIX (KOSDAQ: 229000) announced a partnership to develop oncology assays for QIAGEN’s QIAcuityDx digital PCR platform, according to a press release statement.
GENCURIX becomes the inaugural partner in QIAGEN’s new QIAcuityDx Partnering Program, which aims to expand the menu of in vitro diagnostic (IVD) assays available on the QIAcuityDx Four platform. The collaboration will focus on creating multiplex oncology assays for both tissue and liquid biopsy applications.
"The first partnership in this program with GENCURIX is an exciting moment, giving our oncology testing customers access to high-quality IVD assays that complement other established methods such as qPCR and NGS," said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN.
Under the agreement, GENCURIX will develop multiple oncology assays and pursue IVD regulatory approvals as the legal manufacturer. Once approved, the assays will be marketed through QIAGEN’s global commercial infrastructure.
The partnership leverages QIAGEN’s QIAcuityDx platform, which is part of the QIAcuity family of digital PCR systems that reached more than 2,700 cumulative placements by the end of 2024. With a robust gross profit margin of 67% and strong liquidity position, QIAGEN is well-positioned to support this expansion. The collaboration aims to address growing demand for broader access to high-precision diagnostic assays in clinical laboratories.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.